Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Stock Performance
Cybin Inc. News 152 articles
- Helus Pharma reports FY2026 results with APPROACH Phase 3 enrollment above 88%
- Helus Pharma reports APPROACH Phase 3 enrollment past 86% and launches $50M offering
- Helus Pharma CEO Michael Cola steps down; co-founder Eric So returns as interim CEO
- Helus Pharma begins trading on Nasdaq following Cybin rebrand
- Cybin launches at-the-market equity program of up to US$100 million
- Cybin to rebrand as Helus Pharma and move U.S. listing to Nasdaq
- Cybin reports quarterly results and clinical progress across CYB003 and CYB004 programs
- Cybin closes $175 million registered direct offering
- Cybin announces $175 million registered direct offering
- Cybin completes enrollment in Phase 2 study of CYB004 for generalized anxiety disorder
- Cybin to present at H.C. Wainwright 27th Annual Global Investment Conference
- Cybin shareholders approve full board slate and auditor at annual meeting
- Cybin reports fiscal Q1 2026 results; EMBRACE cleared in Europe/UK, $118.7M cash
- Cybin to present at Canaccord Genuity 45th Annual Growth Conference
- Cybin wins UK MHRA approval to begin EMBRACE, its second pivotal CYB003 depression study
- Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
- Cybin to Participate at the 28th Annual Milken Institute Global Conference
- Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
- Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
- Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
- Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
- Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
- Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
- Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
- Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
- Cybin to Participate at the 2024 Milken Institute Future of Health Summit
- Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
- Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
- Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Cybin Announces Completion of Previously Announced Share Consolidation
- Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
- Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
- Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
- Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
- Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)
- A Swell Of Insider Purchases Follow Cybin Inc.’s Positive Year-End Update
- Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
- Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
Showing the 40 most recent of 152 articles.